Depletion of γ-glutamylcyclotransferase inhibits breast cancer cell growth via cellular senescence induction mediated by CDK inhibitor upregulation by unknown
RESEARCH ARTICLE Open Access
Depletion of γ-glutamylcyclotransferase
inhibits breast cancer cell growth via
cellular senescence induction mediated by
CDK inhibitor upregulation
Kengo Matsumura1, Susumu Nakata1*, Keiko Taniguchi1, Hiromi Ii1, Eishi Ashihara2, Susumu Kageyama3,
Akihiro Kawauchi3 and Tatsuhiro Yoshiki1,3
Abstract
Background: Chromosome 7 open reading frame 24 (C7orf24) was originally identified as a highly expressed
protein in various types of cancer, and later shown to be a γ-glutamylcyclotransferase (GGCT). GGCT depletion in
cancer cells has anti-proliferative effects in vitro and in vivo, and it is therefore considered a promising candidate as
a therapeutic target. However, the cellular events induced by GGCT depletion remain unclear.
Methods: GGCT was depleted by siRNA in MCF7, MDA-MB-231, PC3, A172, Hela, and LNCaP cells. Induction of
cellular senescence was evaluated with senescence-associated β-galactosidase (SA-β-Gal) staining. Expression levels
of p21WAF1/CIP1 and p16INK4A were assessed by qRT-PCR and Western blotting. Effects of simultaneous double
knockdown of p21WAF1/CIP1 and p16INK4A together with GGCT on cell cycle regulation and cell growth was
measured by flow cytometry, and trypan blue dye exclusion test.
Results: We found that GGCT knockdown induces significant cellular senescence in various cancer cells. Cyclin
dependent kinase inhibitor p21WAF1/CIP1 and/or p16INK4A were upregulated in all cell lines tested. Simultaneous
knockdown of p21WAF1/CIP1 recovered the cell cycle arrest, attenuated cellular senescence induction, and rescued
the subsequent growth inhibition in GGCT-silenced MCF7 breast cancer cells. In contrast, in GGCT silenced
MDA-MB-231 breast cancer cells, GGCT depletion upregulated p16INK4A, which played a regulatory role in
senescence induction, instead of p21WAF1/CIP1.
Conclusions: Our findings demonstrate that induction of cellular senescence mediated by the upregulation of
cyclin-dependent kinase inhibitors is a major event underlying the anti-proliferative effect of GGCT depletion in breast
cancer cells, highlighting the potential of GGCT blockade as a therapeutic strategy to induce cellular senescence.
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Background
Chromosome 7 open reading frame 24 (C7orf24) was first
identified by proteomics analysis as a highly expressed pro-
tein in bladder cancer tissues by Kageyama et al. [1, 2] and
later shown to be a γ-glutamylcyclotransferase (GGCT)
[3]. In many cancers, GGCTs are expressed at higher levels
in tumor than non-tumor tissues (58 % in cervical, 38 % in
lung, 72 % in colon, and 46 % in breast cancer), and GGCT
upregulation in tumor tissues is associated with poor clin-
ical outcomes [4].
In previous in vitro studies, forced expression of
GGCT in NIH3T3 cells (mouse fibroblasts cells) in-
creased the rate of cell proliferation, and conversely,
knockdown of GGCT significantly inhibited the growth
of various cancer cells including lung, prostate, bladder,
and breast cancer cells [2]. Regional injection [5] and
systemic administration [6] of GGCT siRNA exerted
anti-tumor effects in xenograft models in vivo. These
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findings suggest that GGCT is a promising candidate as
a therapeutic target and diagnostic marker [7]. However,
the cellular events associated with GGCT depletion have
not been fully characterized to date, and the mechanisms
underlying its inhibitory effect on the growth of cancer
cells remain unknown.
Cellular senescence, which is characterized as perman-
ent growth arrest of cells caused by limited cell division,
was originally described by Hayflick [8]. Senescent cells
undergo unique morphological changes and can become
large, flat, and retractile [9], and they are characterized
by increased SA-β-Gal activity [10]. Cellular senescence
is induced by various stimuli including shortening telo-
meres, DNA damage, activated oncogenes, chromatin
perturbation, and certain cancer therapeutics [9, 11].
The p53-p21WAF1/CIP1 and p16INK4A-pRb pathways
mediate the induction of cellular senescence [11, 12].
Both p21WAF1/CIP1 and p16INK4A are cyclin-dependent
kinase (CDK) regulators [13, 14]. p21WAF1/CIP1 is a crucial
transcriptional target of p53 and inhibits CDK2, causing
cell cycle arrest at the G1 phase. p16INK4A prevents the
phosphorylation and inactivation of pRb, which forms a
complex with E2F. The activity of E2F, a transcription
factor that regulates the expression of genes associated
with cell cycle progression, is suppressed when bound to
pRb [15].
Cellular senescence affects not only normal cells but
also cancer cells [16–18]. Chemotherapeutic agents in-
duce cellular senescence in different cell lines, such as
adriamycin in MCF7 and MDA-MB-231 cells [19, 20],
camptothecin in HCT116 colon cancer cells [21, 22],
and cisplatin in CNE1 nasopharyngeal carcinoma cells
[23]. Recently, molecular targeted therapeutics against
mutated BRAF were shown to exert anticancer effects
via induction of cellular senescence [24]. In vivo studies
showed that treatment with chemotherapeutic agents
induces cellular senescence in HT1080 fibrosarcoma
xenograft tumors treated with doxorubicin [25]. A clinical
study reported that chemotherapeutic drugs increased the
proportion of SA-β-Gal positive senescent cancer cells,
and these senescent cells were frequently co-stained with
p53 and p16INK4A [26].
In the present study, we show that depletion of GGCT
induces marked cellular senescence in various cancer
cells. Knockdown of GGCT in MCF7 breast cancer cells
significantly upregulated p21WAF1/CIP1, and the induction
of cellular senescence and subsequent growth inhib-
ition induced by GGCT depletion was dependent on
p21WAF1/CIP1 upregulation. GGCT depletion induced
the expression of p16INK4A, which regulated senescence
induction in GGCT-silenced MDA-MB-231 breast cancer
cells. To the best of our knowledge, this is the first study
to identify cellular senescence induction mediated by the
upregulation of CDK inhibitors as a major mechanism
underlying the anti-proliferative effect of GGCT
knockdown.
Methods
Cell lines and culture conditions
MCF7, MDA-MB-231, PC3, A172, Hela, and LNCaP
cells were purchased from RIKEN BRC or ATCC and
cultured in DMEM supplemented with 10 % fetal bovine
serum (HyClone, South Logan, UT, USA) and 1 % peni-
cillin and streptomycin. The cells were maintained in
5 % CO2 at 37 °C.
Antibodies
Antibodies against various proteins were obtained from
the following sources: mouse monoclonal antibodies,
GGCT (6-1E, Cosmo Bio, Tokyo, Japan); p21WAF1/CIP1
(BD biosciences, New Jersey, NJ, USA); Caspase-8 (Cell
Signaling Technology, Danvers, MA, USA); β-actin and
GAPDH (Wako Pure Chemical Industries, Osaka,
Japan); rabbit monoclonal antibodies, p16INK4A (Abcam,
Cambridge, MA, USA); PARP-1 (Enzo Life Science,
Farmingdale, NY, USA); Caspase-3 (Cell Signaling Tech-
nology); and p53 (Cell Signaling Technology). Horse
anti-mouse IgG-horseradish peroxidase (HRP) conjugates
were from Vector Laboratories (Burlingame, CA, USA).
Goat anti-rabbit IgG–HRP was from Jackson Immuno
Research Laboratories (West Grove, PA, USA).
Western blot analysis
Cell lysates were prepared with lysis buffer (50 mM Tris–
HCl, 150 mM NaCl, 1 % NP-40, 0.5 % deoxycholate-Na,
and 0.1 % SDS) supplemented with a protease inhibitor
cocktail mix (Nacalai Tesque, Kyoto, Japan). Protein con-
centration was determined using the BCA protein assay
(Bio-RAD, Hercules, CA, USA) according to the manufac-
turer’s protocol. Aliquots containing 20 μg of protein were
separated by SDS-PAGE and transferred to PVDF mem-
branes (Millipore, Billerica, MA, USA). After blocking
with 5 % fat-free dry milk in phosphate buffered saline
with 0.05 % Tween-20 (PBST), the membranes were incu-
bated with primary and secondary antibodies in 3 % BSA
in PBST. The proteins were visualized with the Clarity
Western ECL Substrate (Bio-RAD). Chemiluminescence
was detected by a cooled digital CCD camera, ChemiDoc
XRS Plus (Bio-RAD).
Cell cycle analysis
Cells were seeded in six-well plates and transfected with
GGCT, p21WAF1/CIP1, p16INK4A, or non-targeting siRNA.
The cells were washed and fixed with 70 % ethanol
at −20 °C, and stained with propidium iodide (PI) at a
concentration of 20 μg/ml in the presence of 200 μg/ml
RNase A. DNA content was analyzed using FACSCalibur
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(BD Bioscience). At least 10,000 cells were analyzed for
each sample.
Trypan blue dye exclusion test
MCF7 and MDA-MB-231 cells were transfected with
the indicated siRNAs 1 day after seeding. The standard
trypan blue dye exclusion method was used with 0.4 %
trypan blue solution (Wako).
qRT-PCR analysis
Cells were lysed with Trizol (Thermo Fisher Scientific,
Waltham, MA, USA), and total RNA extracts were puri-
fied with an RNeasy mini kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. cDNA was
synthesized by reverse transcription using the ReverTra
Ace qPCR RT Master Mix (TOYOBO, Osaka, Japan).
qRT-PCR analysis of cDNA was performed with THUN-
DERBIRD SYBR qPCR Mix (TOYOBO) according to the
manufacturer’s protocol using the Light Cycler Nano
System (Roche Diagnostics, Tokyo, Japan). Data were
normalized to ARF1, a house-keeping gene. Primer se-
quences were listed in Additional file 1: Table S1 and S2.
Transfection of siRNA targeting GGCT, p21WAF1/CIP1, and
p16INK4A
Transient transfections were performed using Lipofecta-
mine RNAi MAX (Invitrogen) according to the manu-
facturer’s protocol. Synthesized siRNAs were purchased
from RNAi Co. LTD, Tokyo, or Gene Design Inc, Osaka,
Japan. The siRNA sequences were listed in Additional
file 1: Table S1 and S2. All siRNAs were transfected at a
concentration of 10 nM. For double knockdown experi-
ments, 20 nM of the non-targeting siRNA was transfected
as a control.
Staining of senescence-associated β-galactosidase
Cells were seeded in six-well plates, and transfected with
siRNAs as described above. The cells were stained with
SA-β-Gal 4 days after the transfection using the senes-
cence kit (OZ Bioscience, San Diego, CA, USA) according
to the manufacturer’s protocol. The cells were incubated
with staining solution at 37 °C overnight, and SA-β-Gal
positive cells were counted. For each evaluation, more
than 400 cells were counted in at least 12 fields.
Statistical analysis
All data were confirmed in at least three independent
experiments. The data are expressed as the mean ± S.D.,
unless otherwise indicated. The two-tailed Student’s t-test
was used for calculation of p-values using Excel software.
Results
Knockdown of GGCT suppresses the growth of MCF7 and
MDA-MB-231 breast cancer cells
To study the mechanisms underlying the suppression of
cell growth by GGCT knockdown, the efficiency of
siRNA-mediated GGCT knockdown was first assessed
by Western blotting in MCF7 and MDA-MB-231 breast
cancer cells. The results showed a significant downregu-
lation of GGCT in these cell lines (Fig. 1a). GGCT
knockdown suppressed cell growth in MCF7 and MDA-
MB-231 cells (Fig. 1b). The results of the trypan blue
dye exclusion test revealed that GGCT knockdown signifi-
cantly increased the proportion of dead cells positively
stained with trypan blue in both MCF7 and MDA-MB-
231 cell lines (Fig. 1c).
Fig. 1 GGCT knockdown suppresses the growth of MCF7 and
MDA-MB-231 cells. a MCF7 and MDA-MB-231 cells were transfected
with siRNA targeting GGCT or non-target control siRNA, and the
expression levels of GGCT in total cell lysates harvested 4 days after
the transfection were analyzed by Western blotting. β-actin is shown
as a loading control. b MCF7 and MDA-MB-231 cells were treated
with GGCT siRNA or non-target siRNA. The relative number of trypan
blue-negative viable cells at 1, 4, and 7 days after the transfection
are shown. c Proportion of trypan blue-positive dead cells at 6 days
after transfection. (** p < 0.01)
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Cellular senescence was induced by GGCT knockdown in
various cancer cells
GGCT-depleted cells exhibited a pronounced flat and
enlarged morphology, a characteristic phenotypic change
associated with cellular senescence. Cells were then
stained with SA-β-Gal, a specific marker for senescent
cells [10]. As shown in Fig. 2, knockdown of GGCT in-
duced cellular senescence, as detected by SA-β-Gal
staining, in MCF7 and MDA-MB-231 cells, as well as
other cancer cell lines, including PC3 and LNCaP pros-
tate cancer cells, HeLa cervical cancer cells, and A172
glioblastoma cells.
Cellular senescence induced by GGCT knockdown was
dependent on p21WAF1/CIP1 upregulation in MCF7 cells
Since p21WAF1/CIP1 is an important regulator of cellular
senescence [11, 17, 27, 28], we investigated the effect of
GGCT knockdown on the expression of p21WAF1/CIP1.
Quantitative real-time PCR and Western blot analysis
showed a significant induction of p21WAF1/CIP1 expression
by GGCT knockdown in MCF7 cells (Fig. 3a and b). We
confirmed that expression levels of p21WAF1/CIP1 protein
by GGCT knockdown were also upregulated in PC3,
A172, and Hela cells (Additional file 2: Figure S1). To
determine whether p21WAF1/CIP1 plays a role in the induc-
tion of cellular senescence, the proportion of SA-β-Gal
positive cells was measured in MCF7 cells treated with
p21WAF1/CIP1 targeting siRNA together with GGCT
siRNA. The double knockdown of p21WAF1/CIP1 and GGCT
efficiently suppressed both GGCT and p21WAF1/CIP1
proteins (Fig. 3b), and resulted in a significant de-
crease in the number of SA-β-Gal positive cells com-
pared with that in cells treated with GGCT siRNA
alone (Fig. 3c and d). However, no significant changes
in the proportion of senescent cells were observed in
MDA-MB-231 cells (Fig. 3d), consistent with the very
low expression levels of p21 and absence of significant
induction of p21 by GGCT knockdown (Additional file 2:
Figure S1).
p21WAF1/CIP1-dependent G0/G1 arrest is critical for growth
inhibition induced by knockdown of GGCT in MCF7 cells
Next, we investigated the effect of knockdown of
GGCT alone or together with p21WAF1/CIP1 on cell cycle
Fig. 2 Depletion of GGCT induces cellular senescence in various cancer cells. The indicated cancer cell lines were transfected with siRNA targeting
GGCT or non-target control siRNA, and cellular senescence was evaluated by SA-β-Gal staining at 4 days after transfection. Representative images and
proportion of SA-β-Gal positive cells are shown. Scale bar represents 50 μm
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progression. Transfection of MCF7 cells with GGCT
siRNA led to a significant increase in the percentage of
G0/G1 phase cells (from 74.7 to 90.4 %), and a significant
decrease in S and G2/M phase cells (from 9.3 to 3.0 % and
from 14.4 to 6.1 % respectively, Fig. 4a and b),
whereas no induction of the sub-G1 population was
observed (Fig. 4a). Apoptotic signaling molecules,
such as caspases and PARP, were not activated by
GGCT knockdown (Additional file 3: Figure S2), indi-
cating that the cell death induced after cellular senes-
cence was mediated by a mechanism distinct from
apoptosis. The concurrent knockdown of p21WAF1/CIP1
and GGCT led to a shift in the percentages of G0/G1, G2/
M, and S phase cells (Fig. 4b), demonstrating the important
role of p21WAF1/CIP1 induction in cell cycle regulation.
However, no significant recovery of cell cycle distribution
by p21WAF1/CIP1 knockdown was observed in GGCT-
silenced MDA-MB-231 cells (data not shown). The effect
of p21WAF1/CIP1 on growth inhibition induced by GGCT
knockdown was assessed in MCF7 cells. The double
knockdown of p21WAF1/CIP1 and GGCT led to a signifi-
cant recovery of viable cell numbers in MCF7 cells (Fig. 4c
and d). Moreover, knockdown of p21WAF1/CIP1 signifi-
cantly recovered the dead cell ratio, when compared with
that observed after knockdown of GGCT alone (Fig. 4c,
right panel).
Upregulated p16INK4A plays a role in cellular senescence in
GGCT-depleted MDA-MB-231 cells, but not in MCF7 cells
p21WAF1/CIP1 played a critical role in the inhibition of
MCF7 cell growth induced by GGCT knockdown; however,
p21WAF1/CIP1 was not induced in senescent MDA-MB-231
cells after efficient knockdown of GGCT (Additional file 2:
Figure S1). To identify the mediator of senescence in-
duction in MDA-MB-231 cells, the expression levels of
p16INK4A, an important regulator of senescence [11, 28,
29], were assessed. As shown in Fig. 5a, knockdown of
GGCT significantly induced p16INK4A expression in both
MCF7 and MDA-MB-231 cells. We also confirmed that
expression levels of p16INK4A protein were also induced in
PC3, Hela, and LNCaP cells (Additional file 2: Figure S1).
Knockdown of p16INK4A together with GGCT siRNA sig-
nificantly downregulated p16INK4A to control levels
(Fig. 5a). Knockdown of p16INK4A had no impact on sen-
escence induction in MCF7 cells, consistent with the crit-
ical contribution of p21WAF1/CIP1. By contrast, p16INK4A
knockdown reduced the SA-β-Gal positive senescent
population in MDA-MB-231 cells (Fig. 5b and c).
Induction of p16INK4A plays a role in growth inhibition
caused by GGCT knockdown in MDA-MB-231 cells
Next, we investigated the effect of modulation of p16INK4A
levels on cell cycle regulation in GGCT-depleted cells.
Fig. 3 Induction of senescence by GGCT knockdown depends on p21WAF1/CIP1 upregulation in MCF7 cells. a-b The expression levels of p21WAF1/CIP1 (a)
mRNA and (b) protein in MCF7 cells harvested 4 days after transfection with the indicated siRNAs were analyzed by qRT-PCR and western blotting,
respectively. c Representative images of SA-β-Gal staining 4 days after transfection with the indicated siRNAs in MCF7 and MDA231-MB cells. Scale bar
represents 50 μm. d The numbers of SA-β-Gal positive cells were counted and their ratios in total cells are shown. (** p < 0.01)
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MCF7 cells showed no recovery of cell cycle status by
p16INK4A blockade (Fig. 6a), whereas MDA-MB-231 cells
showed a slight but significant recovery of the G0/G1 ar-
rest and increase of S and G2/M phase by the p16INK4A
blockade (Fig. 6b). The effect of p16INK4A depletion on
growth inhibition induced by GGCT knockdown was
assessed in MDA-MB-231 cells. As shown in Fig. 6c
and d, concomitant knockdown of p16INK4A signifi-
cantly recovered the inhibition of MDA-MB-231 cell
growth caused by GGCT silencing. Moreover, double
knockdown decreased the proportion of dead cells
(Fig. 6d right panel).
Discussion
A growing body of evidence indicates that GGCT is a
promising candidate as a therapeutic target and bio-
marker in cancer [7]. To date, however, the mechanisms
underlying the inhibition of cancer cell growth induced
by GGCT knockdown remain unknown. Here, we show
that depletion of GGCT induces cellular senescence in
different cancer cells, inhibits cell growth, and promotes
cell death.
The temporal dynamics of phenotypic changes in-
duced by GGCT knockdown were unique. GGCT-
silenced cells proliferated slowly for 4 days and showed
no evidence of cell death induction, despite undergoing
morphological changes resulting in flat and enlarged
shapes. Thereafter, from 6 to 7 days post transfection,
the cells started to die, without evidence of nuclear frag-
mentation or activation of apoptotic pathways. GGCT
silencing caused cellular senescence not only in MCF7
and MDA-MB-231 breast cancer cells, but also in other
cancer cells, as detected by SA-β-Gal positivity. This
suggested that the induction of senescence is a universal
phenomenon upon GGCT depletion.
Cellular senescence is defined as permanent cell cycle
arrest, and senescent cells lose proliferative potency
[16, 17]. Various molecular mechanisms of cellular
senescence have been proposed [9, 11, 28]. Among
them, the p21WAF1/CIP1 mediated induction of cellular
senescence was shown in various cellular contexts [11].
Microarray-based studies suggest that p21WAF1/CIP1 ex-
pression positively correlates with the induction of genes
associated with senescence [30]. Johmura et al. reported
Fig. 4 Upregulation of p21WAF1/CIP1 is critical for G0/G1 arrest and consequent growth inhibition by GGCT knockdown. a-b The distribution of cell
cycle phases in MCF7 cells was analyzed by flow cytometry 4 days after transfection with the indicated siRNAs. Representative histograms (a) and
quantified distributions are shown (b). c-d The number of Trypan blue-negative viable MCF cells (c) and the proportion of dead cells (d) at 7 days
after transfection with the indicated siRNAs are shown. (* p < 0.05, ** p < 0.01)
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Fig. 5 p16INK4A regulates GGCT knockdown-induced senescence in MDA-MB-231 cells. a The expression levels of p16INK4A in MCF7 and MDA-MB-231
cells harvested 4 days after transfection with the indicated siRNAs were analyzed by western blotting. β-actin is shown as loading controls.
b Representative images of SA-β-Gal staining 4 days after transfection with the indicated siRNAs in MCF7 and MDA231-MB cells. Scale
bar represents 50 μm. c The number of SA-β-Gal positive cells was counted and their ratios in total cells are shown. (** p < 0.01)
Fig. 6 Blockage of p16INK4A induction attenuates cell cycle arrest and growth inhibition caused by GGCT knockdown. a-b The distribution of
cell cycle phases in MCF7 (A) and MDA-MB-231 (b) cells was analyzed by flow cytometry 4 days after transfection with the siRNAs indicated.
c-d Representative images of MDA-MB-231 cells (c), the number of Trypan blue-negative viable MDA-MB-231 cells (d, left panel), and the proportion
of dead cells (d, right panel) at 7 days after transfection with the indicated siRNAs are shown. (* p < 0.05, ** p < 0.01)
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that p21WAF1/CIP1 is upregulated at the early stages of cel-
lular senescence [12]. Our results also showed that
p21WAF1/CIP1 was upregulated in GGCT-silenced MCF7
cells at the mRNA and protein levels (Fig. 3a and b). In
parallel with the upregulation of p21WAF1/CIP1, GGCT-
depletedMCF7 cells stained positive for SA-β-Gal (Fig. 3c),
indicating the induction of cellular senescence. The induc-
tion of cellular senescence was dependent on the upre-
gulation of p21WAF1/CIP1 in MCF7 cells, as demonstrated
by the effect of simultaneous depletion of GGCT and
p21WAF1/CIP1 (Fig. 3d).
In addition to its role as an effector of cellular senes-
cence, p21WAF1/CIP1 has many functions, including cell
cycle regulation and the modulation of apoptotic path-
ways [27, 31]. As a member of the Cip and Kip family of
CDK inhibitors [27], p21WAF1/CIP1 is a key regulator of
cell cycle checkpoints at G1 and S phases [27, 31]. Con-
sistent with this, the marked induction of p21WAF1/CIP1
upon GGCT silencing resulted in cell cycle arrest at the
G0/G1 phase in MCF7 cells (Fig. 4a). Our data using
double knockdown clearly demonstrate that the induction
of G0/G1 arrest occurred in a p21WAF1/CIP1-dependent
manner (Fig. 4c and d).
p53 is a key transactivator of p21WAF1/CIP1 [32]. Al-
though MCF7 cells have wild-type p53 [21], GGCT
knockdown did not induce p53 in MCF7 and MDA-
MB-231 cells (Additional file 4: Figure S3), suggesting
that p21WAF1/CIP1 upregulation was mediated by p53-
independent pathways in MCF7 cells. In addition,
p21WAF1/CIP1 was significantly upregulated in PC3 cells
(Additional file 2: Figure S1), which harbor a null p53
mutant, suggesting that p21WAF1/CIP1 induction by GGCT
depletion was mediated by p53-independent mechanisms.
Supporting these findings, multiple p53-independent
mechanisms of transactivation of p21WAF1/CIP1 are
known [29]. Further investigations are needed to clar-
ify the precise mechanisms underlying the upregulation
of p21WAF1/CIP1.
The attenuation of the G0/G1 cell cycle arrest and
subsequent cellular senescence by simultaneous knock-
down of p21WAF1/CIP1 resulted in significant recovery of
cell growth and decrease of dead cell population in
GGCT-depleted MCF7 cells. These results indicate that
the induction of cellular senescence due to the perman-
ent loss of proliferative potential led to cell death induc-
tion, highlighting p21WAF1/CIP1 as an important mediator
of GGCT knockdown-mediated growth suppression in
MCF7 cells.
In contrast to the upregulation of p21WAF1/CIP1 in
MCF7 cells, depletion of GGCT induced the upregula-
tion of p16INK4A (Fig. 5a) in MDA-MB-231 cells, but not
that of p21WAF1/CIP1. p16INK4A, a CDK inhibitor, is a
p53-independent regulator of oncogene-induced cell
cycle arrest and senescence [29, 32]. We showed that
blocking p16INK4A upregulation, at least in part, attenu-
ated the induction of cellular senescence and subsequent
suppression of cell growth accompanied by a massive
induction of cell death. These results suggest that
p16INK4A upregulation mediated cellular senescence
leading to the inhibition of cell growth in GGCT-
silenced MDA-MB-231 cells. However, the simultaneous
knockdown of p16INK4A could not recover cellular sen-
escence as efficiently as in the case of p21WAF1/CIP1 in
MCF7 cells, suggesting that other molecules may play a
role in the induction of senescence by GGCT depletion
in MDA-MB-231 cells (Fig. 5b and c).
Conclusions
Taken together, our results indicate that depletion of
GGCT induces CDK inhibitor(s) that mediate cell cycle
arrest and subsequent cellular senescence in various can-
cer cells, leading to the significant suppression of cell
growth. The CDK inhibitor(s) induced by GGCT deple-
tion may vary according to cell type. Our results shed
new light on the mechanisms underlying the anticancer
effects of GGCT-targeting and highlight the potential of
GGCT blockade as a therapeutic strategy to induce
cellular senescence in cancer cells.
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